Orphazyme AS (CHIX:ORPHAC) Other Long-Term Liabilities : kr0.00 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Other Long-Term Liabilities?

Orphazyme AS's other long-term liabilities for the quarter that ended in Jun. 2022 was kr0.00 Mil.

Orphazyme AS's quarterly other long-term liabilities increased from Jun. 2021 (kr15.01 Mil) to Dec. 2021 (kr28.29 Mil) but then declined from Dec. 2021 (kr28.29 Mil) to Jun. 2022 (kr0.00 Mil).

Orphazyme AS's annual other long-term liabilities increased from Dec. 2019 (kr0.07 Mil) to Dec. 2020 (kr1.18 Mil) and increased from Dec. 2020 (kr1.18 Mil) to Dec. 2021 (kr28.29 Mil).

Orphazyme AS Other Long-Term Liabilities Historical Data

The historical data trend for Orphazyme AS's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Other Long-Term Liabilities Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Other Long-Term Liabilities

Get a 7-Day Free Trial

Orphazyme AS Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Other Long-Term Liabilities	Get a 7-Day Free Trial									-	-	-	-	-

Orphazyme AS Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Orphazyme AS Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS Headlines

No Headlines